Eculizumab: Another breakthrough

Robert A. Brodsky

doi:10.1182/blood-2017-01-760496

Eculizumab: Another breakthrough

Robert A. Brodsky

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

6 Scopus citations

Abstract

In this issue of Blood, Harder et al demonstrate that breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with eculizumab is due to strong activation of the complement cascade, leading to higher C3b density, which may cause a conformation change limiting the ability of eculizumab to block terminal complement.¹

Original language	English (US)
Pages (from-to)	922-923
Number of pages	2
Journal	Blood
Volume	129
Issue number	8
DOIs	https://doi.org/10.1182/blood-2017-01-760496
State	Published - Feb 23 2017

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2017-01-760496

Cite this

@article{2bec44e2455e4a31a1d220099c18f285,

title = "Eculizumab: Another breakthrough",

abstract = "In this issue of Blood, Harder et al demonstrate that breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with eculizumab is due to strong activation of the complement cascade, leading to higher C3b density, which may cause a conformation change limiting the ability of eculizumab to block terminal complement.1",

author = "Brodsky, {Robert A.}",

note = "Publisher Copyright: {\textcopyright} 2017 by The American Society of Hematology.",

year = "2017",

month = feb,

day = "23",

doi = "10.1182/blood-2017-01-760496",

language = "English (US)",

volume = "129",

pages = "922--923",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "8",

}

TY - JOUR

T1 - Eculizumab

T2 - Another breakthrough

AU - Brodsky, Robert A.

PY - 2017/2/23

Y1 - 2017/2/23

N2 - In this issue of Blood, Harder et al demonstrate that breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with eculizumab is due to strong activation of the complement cascade, leading to higher C3b density, which may cause a conformation change limiting the ability of eculizumab to block terminal complement.1

AB - In this issue of Blood, Harder et al demonstrate that breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with eculizumab is due to strong activation of the complement cascade, leading to higher C3b density, which may cause a conformation change limiting the ability of eculizumab to block terminal complement.1

UR - http://www.scopus.com/inward/record.url?scp=85014944221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014944221&partnerID=8YFLogxK

U2 - 10.1182/blood-2017-01-760496

DO - 10.1182/blood-2017-01-760496

M3 - Comment/debate

C2 - 28232621

AN - SCOPUS:85014944221

SN - 0006-4971

VL - 129

SP - 922

EP - 923

JO - Blood

JF - Blood

IS - 8

ER -

Eculizumab: Another breakthrough

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this